Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
330.34
+11.49 (3.60%)
At close: Apr 6, 2026, 4:00 PM EDT
320.61
-9.73 (-2.95%)
After-hours: Apr 6, 2026, 7:56 PM EDT
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,500 employees as of December 31, 2025. The number of employees increased by 270 or 12.11% compared to the previous year.
Employees
2,500
Change (1Y)
270
Growth (1Y)
12.11%
Revenue / Employee
$1,485,575
Profits / Employee
$125,499
Market Cap
43.81B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,500 | 270 | 12.11% |
| Dec 31, 2024 | 2,230 | 130 | 6.19% |
| Dec 31, 2023 | 2,100 | 98 | 4.90% |
| Dec 31, 2022 | 2,002 | 337 | 20.24% |
| Dec 31, 2021 | 1,665 | 212 | 14.59% |
| Dec 31, 2020 | 1,453 | 130 | 9.83% |
| Dec 31, 2019 | 1,323 | 258 | 24.23% |
| Dec 31, 2018 | 1,065 | 316 | 42.19% |
| Dec 31, 2017 | 749 | 235 | 45.72% |
| Dec 31, 2016 | 514 | 145 | 39.30% |
| Dec 31, 2015 | 369 | 113 | 44.14% |
| Dec 31, 2014 | 256 | 91 | 55.15% |
| Dec 31, 2013 | 165 | 36 | 27.91% |
| Dec 31, 2012 | 129 | 13 | 11.21% |
| Dec 31, 2011 | 116 | -56 | -32.56% |
| Dec 31, 2010 | 172 | -6 | -3.37% |
| Dec 31, 2009 | 178 | 8 | 4.71% |
| Dec 31, 2008 | 170 | 41 | 31.78% |
| Dec 31, 2007 | 129 | 7 | 5.74% |
| Dec 31, 2006 | 122 | 28 | 29.79% |
| Dec 31, 2005 | 94 | 23 | 32.39% |
| Dec 31, 2004 | 71 | 11 | 18.33% |
| Dec 31, 2003 | 60 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
ALNY News
- 13 hours ago - An S&P 500 change may be imminent. These stocks are leading contenders to join the index. - Market Watch
- 7 days ago - New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management - Business Wire
- 13 days ago - Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis - Business Wire
- 13 days ago - Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association - Business Wire
- 26 days ago - How Alnylam Stock Weathers Market Shocks - Forbes
- 27 days ago - Alnylam to Webcast TTR Investor Webinar - Business Wire
- 4 weeks ago - Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Benzinga
- 4 weeks ago - Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - Reuters